NO20002078D0 - Komponenter til forbedret hudpenetrasjon - Google Patents

Komponenter til forbedret hudpenetrasjon

Info

Publication number
NO20002078D0
NO20002078D0 NO20002078A NO20002078A NO20002078D0 NO 20002078 D0 NO20002078 D0 NO 20002078D0 NO 20002078 A NO20002078 A NO 20002078A NO 20002078 A NO20002078 A NO 20002078A NO 20002078 D0 NO20002078 D0 NO 20002078D0
Authority
NO
Norway
Prior art keywords
components
skin penetration
improved skin
improved
penetration
Prior art date
Application number
NO20002078A
Other languages
English (en)
Other versions
NO20002078L (no
Inventor
Anthony David Ormerod
Arthur Winfield
Original Assignee
Univ Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aberdeen filed Critical Univ Aberdeen
Publication of NO20002078D0 publication Critical patent/NO20002078D0/no
Publication of NO20002078L publication Critical patent/NO20002078L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
NO20002078A 1997-11-07 2000-04-19 Komponenter til forbedret hudpenetrasjon NO20002078L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723669.9A GB9723669D0 (en) 1997-11-07 1997-11-07 Skin penetration enhancing components
PCT/GB1998/003317 WO1999024036A1 (en) 1997-11-07 1998-11-05 Skin penetration enhancing components

Publications (2)

Publication Number Publication Date
NO20002078D0 true NO20002078D0 (no) 2000-04-19
NO20002078L NO20002078L (no) 2000-07-06

Family

ID=10821813

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002078A NO20002078L (no) 1997-11-07 2000-04-19 Komponenter til forbedret hudpenetrasjon

Country Status (33)

Country Link
US (2) US6958153B1 (no)
EP (2) EP1632231A3 (no)
JP (1) JP2001522801A (no)
KR (1) KR20010031741A (no)
CN (1) CN1115148C (no)
AR (1) AR014011A1 (no)
AT (1) ATE332134T1 (no)
AU (1) AU759326B2 (no)
BG (1) BG104370A (no)
BR (1) BR9815264A (no)
CA (1) CA2309159C (no)
CY (1) CY1105243T1 (no)
DE (1) DE69835163T2 (no)
DK (1) DK1028727T3 (no)
EA (1) EA003616B1 (no)
EE (1) EE04390B1 (no)
ES (1) ES2268795T3 (no)
GB (1) GB9723669D0 (no)
GE (2) GEP20043171B (no)
HR (1) HRP20000233A2 (no)
HU (1) HUP0003675A3 (no)
ID (1) ID24662A (no)
IL (1) IL135978A0 (no)
NO (1) NO20002078L (no)
NZ (3) NZ520449A (no)
PL (1) PL340710A1 (no)
PT (1) PT1028727E (no)
SK (1) SK6622000A3 (no)
TR (1) TR200001238T2 (no)
TW (1) TW557218B (no)
UA (1) UA73274C2 (no)
WO (1) WO1999024036A1 (no)
ZA (1) ZA9810111B (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
WO2001066117A1 (en) * 2000-03-09 2001-09-13 Ian Andrew Whitcroft Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
EP1389209B1 (en) * 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1455888B1 (en) 2001-08-29 2009-04-29 PharmaKodex Limited Topical administration device
CN1617709A (zh) * 2001-12-13 2005-05-18 兰贝克赛实验室有限公司 克拉霉素的稳定局部制剂
WO2003097647A1 (en) * 2002-05-15 2003-11-27 Endocyte, Inc. Vitamin-mitomycin conjugates
DK1592457T3 (da) 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
WO2004071398A2 (en) * 2003-02-17 2004-08-26 Cipla Ltd Pharmaceutical patch
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
GB0307865D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20050079228A1 (en) * 2003-05-30 2005-04-14 Ashish Jaiswal Clear, stable topical compositions of clarithromycin and processes for their preparation
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
EP1699415A4 (en) * 2003-12-29 2008-01-09 Univ Ramot ASSAY FOR THE DETECTION OF RAPAMYCIN AND RAPAMYCIN ANALOGUE
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
US20080207670A1 (en) * 2004-09-16 2008-08-28 Bayer Healthcare Ag Dermally Applicable Formulations For Treating Skin Diseases in Animals
EP3025704B1 (en) * 2005-03-10 2019-01-16 3M Innovative Properties Company Methods of reducing microbial contamination
EP1863816B1 (en) * 2005-03-16 2014-06-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
AU2006279304A1 (en) 2005-08-19 2007-02-22 Endocyte, Inc. Multi-drug ligand conjugates
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne
US9205080B2 (en) 2006-11-16 2015-12-08 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN104127878A (zh) * 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
BRPI0812970A2 (pt) * 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
WO2009018447A2 (en) 2007-07-31 2009-02-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US20100086581A1 (en) * 2008-10-07 2010-04-08 Ernest Bove Method for purpura reduction and prevention
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
CA2822746A1 (en) * 2009-12-21 2011-06-30 Sarah Bacus Compositions and methods for treatment of vitiligo
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
US20120022095A1 (en) * 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
CA2825786A1 (en) * 2011-01-31 2012-08-09 Osaka University Externally-used drug for treating skin disorder and method for producing same
US20130102572A1 (en) * 2011-04-12 2013-04-25 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EP2908818A4 (en) 2012-10-16 2016-07-13 Endocyte Inc CONJUGATES OF DRUG DELIVERY CONTAINING ARTIFICIAL AMINO ACIDS AND METHODS OF USE
WO2014117035A1 (en) * 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
JPWO2015199248A1 (ja) * 2014-06-26 2017-04-27 国立大学法人大阪大学 発汗抑制剤
KR20180081501A (ko) 2015-09-24 2018-07-16 드렉셀유니버시티 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법
FR3050206B1 (fr) 2016-04-15 2018-05-11 Engie Dispositif et procede d'hydrogenation pour produire du methanol et dispositif et procede de cogeneration de methanol et de methane de synthese
WO2018031789A1 (en) 2016-08-10 2018-02-15 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
BR112021016296A2 (pt) 2019-02-20 2021-11-09 Ai Therapeutics Inc Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele
EP4114357B1 (en) 2020-03-02 2025-10-01 Shanghai Aucta Pharmaceuticals Co., Ltd. Topical formulations containing mtor inhibitors
FR3112537B1 (fr) 2020-07-14 2023-03-31 Engie Dispositif et procédé de production hybride de dihydrogène de synthèse et/ou de méthane de synthèse
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31769A (en) * 1861-03-26 Water-elevator
US3376646A (en) * 1967-03-30 1968-04-09 Herman E. Radke Template tracer
US4335115A (en) * 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4954487A (en) * 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
CA1165240A (en) 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
AU656145B2 (en) * 1990-09-04 1995-01-27 Astellas Pharma Inc. Ointments containing tricyclic compound
DE59309714D1 (de) * 1992-08-04 1999-09-09 Rhone Poulenc Rorer Gmbh Pharmazeutische und/oder kosmetische Zubereitung
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
FI90649C (fi) 1993-02-01 1994-03-10 Pauli Groenberg Menetelmä hevosen satulan sovittamiseksi hevosen selkään
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
JPH06345646A (ja) 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
JPH08133979A (ja) 1994-09-16 1996-05-28 Sando Yakuhin Kk 局所適用薬剤組成物
ATE299017T1 (de) 1994-10-26 2005-07-15 Novartis Pharma Gmbh Arzneimittel
US5648389A (en) * 1995-10-27 1997-07-15 Medicis Pharmaceutical, Inc. Compositions for the treatment of dermatological disorders and methods for their use

Also Published As

Publication number Publication date
US6958153B1 (en) 2005-10-25
GEP20032884B (en) 2003-02-25
HUP0003675A2 (hu) 2001-04-28
PT1028727E (pt) 2006-11-30
GEP20043171B (en) 2004-02-25
ZA9810111B (en) 1999-05-07
EE200000279A (et) 2001-10-15
JP2001522801A (ja) 2001-11-20
NZ520449A (en) 2004-04-30
EP1028727A1 (en) 2000-08-23
EA200000461A1 (ru) 2000-10-30
DE69835163D1 (de) 2006-08-17
UA73274C2 (en) 2005-07-15
GB9723669D0 (en) 1998-01-07
CA2309159A1 (en) 1999-05-20
EA003616B1 (ru) 2003-08-28
ES2268795T3 (es) 2007-03-16
CA2309159C (en) 2009-03-17
AU759326B2 (en) 2003-04-10
NZ530752A (en) 2005-05-27
NO20002078L (no) 2000-07-06
US20050239724A1 (en) 2005-10-27
HRP20000233A2 (en) 2001-02-28
TR200001238T2 (tr) 2001-01-22
EP1028727B1 (en) 2006-07-05
EP1632231A2 (en) 2006-03-08
CN1115148C (zh) 2003-07-23
EE04390B1 (et) 2004-12-15
DE69835163T2 (de) 2007-05-31
SK6622000A3 (en) 2001-01-18
TW557218B (en) 2003-10-11
PL340710A1 (en) 2001-02-26
BR9815264A (pt) 2001-08-14
ATE332134T1 (de) 2006-07-15
WO1999024036A1 (en) 1999-05-20
AR014011A1 (es) 2001-01-31
AU1040899A (en) 1999-05-31
EP1632231A3 (en) 2008-01-23
CN1278173A (zh) 2000-12-27
KR20010031741A (ko) 2001-04-16
ID24662A (id) 2000-07-27
HUP0003675A3 (en) 2001-05-28
NZ504076A (en) 2002-12-20
IL135978A0 (en) 2001-05-20
BG104370A (en) 2000-12-29
DK1028727T3 (da) 2006-10-23
CY1105243T1 (el) 2010-03-03

Similar Documents

Publication Publication Date Title
NO20002078L (no) Komponenter til forbedret hudpenetrasjon
DK0948308T3 (da) Fremgangsmåder til behandling af hudpigmentering
DK1226906T3 (da) Skaft til barberapparat
DE69926739D1 (de) Wasserdampf erzeugende hautabdeckung
DK0977612T3 (da) Applikator til halvfaste medikamenter
IS5058A (is) Samverkandi súlfónýlþvagefnis-glitasónsblöndur við sykursýki
MX208461B (es) Polisacaridos de termofraguado
NO983836D0 (no) Truse til engangsbruk
FI971620A7 (fi) Autentikointimenetelmä
DE69825982D1 (de) Spritze
DK0925022T3 (da) Forbedringer med relation til hudprikkenåle
DE59807782D1 (de) Punktionsset
DK0953072T3 (da) Teknisk væv til airbags
NO20001494L (no) Overligger
DK0926985T3 (da) Forbedringer vedrørende hudpunkteringsapparater
ID15967A (id) Agen terapi diabetes
DE69833493D1 (de) Gewebe
PT1015447E (pt) Derivado piperidinilmetiloxazolidinona
DE59506751D1 (de) Penetrationshilfsmittel
KR970053540U (ko) 침시술용 침관
FR2770103B1 (fr) Bigoudi perfectionne
SI1028727T1 (sl) Sestavine za izboljsanje penetracije v kozo
KR980000116U (ko) 발광등 부자
DK0961610T3 (da) Hudpræparat
PT9496T (pt) Enfuste aperfeicoado